Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
Isa Neshandar Asli1, Nariman Mosaffa, Mehdi Mogharrabi
1Department of Nuclear Medicine, Taleghani Hospital.
Nuclear Medicine Communications
|January 15, 2010
Summary
Technetium-methoxyisobutyl isonitrile (Tc-MIBI) cardiac imaging poses no significant cytogenetic risk. However, radioactive iodine (I) used for thyroid cancer therapy can cause detrimental effects, necessitating careful consideration during treatment.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
- Cytogenetics
Background:
- Radiopharmaceuticals are widely used in cardiac imaging and thyroid cancer therapy.
- Concerns exist regarding potential cytogenetic damage from these agents.
Purpose of the Study:
- To evaluate the cytogenetic effects of Tc-methoxyisobutyl isonitrile (Tc-MIBI) and radioactive iodine (I).
- To assess risks associated with Tc-MIBI for cardiac imaging and I for thyroid cancer treatment.
Main Methods:
- Mononuclear leukocytes were isolated before and after radiopharmaceutical administration.
- Micronuclei frequency and apoptosis were assessed in cultured cells.
Main Results:
- Tc-MIBI showed a statistically insignificant increase in micronuclei.
- Radioactive iodine significantly increased micronuclei frequency at therapeutic doses (P<0.05).
Conclusions:
- Tc-MIBI cardiac imaging appears safe with no significant cytogenetic alterations.
- Radioactive iodine therapy for thyroid cancer may have deleterious cytogenetic effects that require consideration.
